Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis

Arthritis & Rheumatism

Volumn 38, Issue 11, 1995, Pages 1595-1603

  Mladenovic, Vlastimir ^a   Domljan, Zlatko ^b   Rozman, Blaz ^b   Jajic, Ivo ^c   Mihajlovic, Dimitrije ^d   Dordevic, Jovan ^d   Popovic, Milan ^e   Dimitrijevic, Miroslava ^f   Zivkovic, Milutin ^g   Campion, Giles ^h   Musikic, Predrag ^h,j   Löw‐Friedrich, Iris ^h   Oed, Christine ^h   Seifert, Hildegard ^h   Strand, Vibeke ⁱ  

^a INSTITUTE OF RHEUMATOLOGY   (Czech Republic)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^c KBC Zagreb   (Croatia)

^d Institute for Rheumatic and Cardiovascular Disease ^*

^e UNIVERSITY OF DEFENCE   (Serbia)

^f UNIVERSITY OF BELGRADE   (Serbia)

^g Institut Igale ^*

^h SANOFI   (France)

ⁱ STANFORD UNIVERSITY   (United States)

^j Stanford University ^*  (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; AZATHIOPRINE; CORTICOSTEROID; GOLD; IMMUNOSUPPRESSIVE AGENT; ISOXAZOLE DERIVATIVE; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE;

ADULT; AGED; ALOPECIA; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; MALE; MIDDLE AGED; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 0028792355     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.1780381111     Document Type: Article

References (34)

1. Comparison of azathioprine, cyclophosphamide, and gold in rheumatoid arthritis
2. Low‐dose methotrexate compared with azathioprine in the treatment of rheumatoid arthritis: a twenty‐four‐week controlled clinical trial
3. Efficacy of low‐dose methotrexate in rheumatoid arthritis
4. Comparison of low‐dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial
5. Weekly pulse methotrexate in rheumatoid arthritis: clinical and immunologic effects in a randomized, double bline study
6. Cyclosporine in rheumatoid arthritis: a double‐blind, placebo‐controlled study in 52 patients
7. Low‐dose cyclosporin versus placebo in patients with rheumatoid arthritis
8. Effects of leflunomide on immune responses and models of inflammation
9. Disease modifying activity of HWA 486 on the development of SLE in MRL/I mice
10. Development of autoimmunity in MRL/I mice and the effect of drugs on this murine disease
11. Leflunomide inhibits experimental autoimmune tubulointerstitial nephritis in rats
12. Therapeutic effects of leflunomide, a new antirheumatic drug, on glomerulonephritis induced by antibasement membrane antibody in rats
13. The use of the murine chronic graft versus host disease, a model for SLE, for drug discovery
14. Leflunomide: a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplant rejection
15. Prevention of kidney and skin graft rejection in rats by leflunomide
16. Immunosuppressive effects of leflunomide in. a cardiac allograft model
17. Suppression of natural xenophile antibodies with the novel immunosuppressive drug leflunomide
18. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
19. A seven‐day variability study of 499 patients with rheumatoid arthritis
20. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials
21. Measurement of patient outcome in arthritis
22. Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis
23. Analysis of improvement in individual rheumatoid arthritis patients treated with disease‐modifying antirheumatic drugs, based on the findings in patients treated with placebo
24. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis
25. Long term administration of leflunomide to patients with rheumatoid arthritis (abstract)
26. Methotrexate in rheumatoid arthritis
27. Sulphasalazine in rheumatoid arthritis: a double‐blind comparison of sulphasalazine with placebo and sodium aurothiomalate
28. Sulfasalazine in rheumatoid arthritis: a double‐blind, placebo‐controlled trial
29. A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis
30. Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial
31. Multicenter trial of an anti‐CD5 immunoconjugate in rheumatoid arthritis (abstract)
32. Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity